RheumNow Podcast – ACR 20 is Coming to Town (10.30.20)

Save

Dr Jack Cush overviews the RheumNow commitment, upcoming bonus coverage of ACR20 and the good news and journal reports from the past week on RheumNow.com

FDA Invites Patient Input on Systemic Sclerosis Drug Development

Save

While there have been several promising new agents for systemic sclerosis, many have failed - with all noting the difficulties in appropriate outcomes and endpoints for clinical trials. With this in mind, the FDA was interested in hearing patients’ perspectives on systemic sclerosis and new drug development, and held a virtual meeting on 10/13/20.

Guselkumab, an IL-23 Inhibitor, Effective in Psoriatic Arthritis

Save

The DISCOVER‐2 trial has shown that guselkumab, an interleukin‐23p19 was shown to be safe and effective in biologic‐naïve psoriatic arthritis (PsA) patients in a one year study.

Fibromyalgia Therapies Show Limited Evidence of Pain and QOL Reduction

Save

JAMA Internal Medicine has published a review showing that most currently approved therapies for fibromyalgia (FM) do not have high-quality evidence to support their use; with some reducing pain or improving quality of life (QOL) in the short term, but overall effect size is not impressive.

Vedolizumab Promising in Immune-Related GI Events

Save

Vedolizumab (Entyvio) was superior to infliximab (Remicade) for treating immune-mediated diarrhea and colitis (IMDC), a researcher reported.

Immune Necrotizing Myopathy

Save

A full read review of immune-mediated necrotizing myopathy is portrayed as a distinct subtype of inflammatory myopathies first described in 2004.

Telemedicine Outcomes in RA Care

Save

A new short‐term follow‐up study has shown no significant difference in outcomes and quality measures in patients with RA who were managed by telemedicine (compared to usual in-person care).

FDA Hearing on COVID-19 Vaccines

Save

Yesterday the Food and Drug Administration's (FDA) "Vaccines and Related Biological Products Advisory Committee" conve

RheumNow Podcast – Back Talk: Questions from Listeners (10.23.20)

Save

Dr. Jack Cush reviews the news, journal reports, survey results and "Back Talk" questions from Rheums.

Remdesivir FDA Approved for Hospitalized COVID-19

Save

The FDA has approved Gilead Sciences Inc’s antiviral drug remdesivir for treating patients hospitalized with COVID-19, making it the first and only drug approved for the disease in the United States.

Clinical Trial Boom or Bust in Severe COVID-19

Save

A number of recently published clinical trials are further defining the efficacy and outcomes of tocilizumab or remdesivir in treating SARs-CoV-2 infection.

Remdesivir

Biologic Use for Arthritis Linked With Depression and Anxiety

Save

In a recent study of patients with inflammatory rheumatic diseases, the initiation of a biologic treatment or switching to another biologic was associated with an increased likelihood of the use of antidepressants and anxiolytics, reported Petros P. Sfikakis, MD, of the National and Kapodistrian University of Athens, and colleagues in RMD Open: Rheumatic & Musculoskeletal Diseases.

Outpatient Visits Return to Pre-COVID Rates

Save

The COVID-19 pandemic dramatically impacted outpatient care - numbers, scope, quality, etc, but a recent study suggests that while COVID has changed the scope of care, the numbers of outpatient visits have risen to near pre-pandemic numbers.

TNF Inhibitors or non-TNF Biologics - First Best Choice?

Save

Prospective observational findings from the CORRONA registry of rheumatoid arthritis (RA) patients compared clinical outcomes between initial aggressive therapy using either a tumour necrosis factor inhibitor (TNFi) or a non-TNFi (biological disease-modifying antirheumatic drugs (bDMARDs) and tar